Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.48 |
| ▸ | FNTB | P49356 | 8/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8390629 | 1.00 | FNTA (0.48) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL9055531 | 0.97 | FNTA (0.47) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL9055548 | 0.97 | FNTA (0.47) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8296917 | 0.94 | FNTA (0.44) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8296916 | 0.94 | FNTA (0.44) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8387800 | 0.93 | FNTA (0.44) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8387810 | 0.93 | FNTA (0.44) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8392085 | 0.92 | FNTA (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8392092 | 0.92 | FNTA (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL8392100 | 0.91 | FNTA (0.48) | FNTAFNTBPGGT1BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | claimed |
| EP-1811984-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Exonhit Therapeutics SA (FR) | 2007-08-01 | — | — | EP | claimed |
| WO-2006051423-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE | EXONHIT THERAPEUTICS SA (FR) | 2006-05-18 | — | — | WO | claimed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | claimed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | claimed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | claimed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20180263985-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2018-09-20 | — | — | US | disclosed |
| EP-3349757-A1 | MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3166607-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2017048727-A1 | MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20050143817-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263985-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | FNTA 3299/4885FNTB 2343/4885PGGT1B 1733/4885 |
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | TLR7, TLR3, TLR6 | FNTA 3930/4885FNTB 2672/4885PGGT1B 1503/4885 |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | FNTA 2488/4885FNTB 1938/4885PGGT1B 2079/4885 |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 126/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | FNTA 3299/4885FNTB 2343/4885PGGT1B 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.